Company Overview - Clene Inc. is a late clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) [1][3] - The company aims to improve mitochondrial health and protect neuronal function through its investigational therapy CNM-Au8, which targets mitochondrial function and the NAD pathway while reducing oxidative stress [3] Upcoming Events - Clene management will participate in a fireside chat at the 37th Annual Roth Conference on March 18, 2025, at 9:20 am PST [2] - The event will be conducted in a virtual format, and 1x1 investor meetings will also be hosted [2] Research and Development - Clene's research and development operations are based in Maryland, while the company is headquartered in Salt Lake City, Utah [3]
Clene to Present at the 37TH Annual Roth Conference